BeiGene, Zai Lab Look To Clear US Delisting Uncertainties
US Exit A Viable Option?
Executive Summary
US-listed Chinese biotechs are switching auditors in hopes of satisfying the US securities regulator's demands - but legal experts also see other considerations at play.
You may also be interested in...
Delisting Looms As More US-Listed China Companies Seek To Move Closer Home
After five state-owned US-listed Chinese firms announce plans to delist from the US stock market, private firms such as Alibaba follow the lead.
Paradox Of China Biotech And What Lies Ahead In 2023
The hard going could get even tougher as a funding crunch continues for China’s biotech sector, which is being hit by a paradox that could see more pain ahead, leading investors to take the pulse of the sector as the Year of the Rabbit starts.
Cold Water On Already Frozen Sector: Industry Growing Wary Of China Price Cuts
From orphan to cancer drugs, more products have had their prices cut in the latest round of reimbursement negotiations in China. Although the 60% average across 100 medicines was considered mild given it didn’t go beyond the previous year, it was still chilling and is prompting more firms, both multinational and domestic, to walk away from the process.